Assessment of Vancomycin Pharmacokinetics and Dose Regimen Optimisation in Preterm Neonates

dc.contributor.author	Mulubwa, Mwila
dc.contributor.author	Griesel, Heletje Aletta
dc.contributor.author	Mugabo, Pierre E.
dc.date.accessioned	2020-12-15T09:08:37Z
dc.date.available	2020-12-15T09:08:37Z
dc.date.issued	2020
dc.identifier.citation	9. Mulubwa, M. et al (2020). Assessment of Vancomycin Pharmacokinetics and Dose Regimen Optimisation in Preterm Neonates. Drugs in R and D ,20(2), 105-113	en_US
dc.identifier.issn	1179-6901
dc.identifier.uri	https://doi.org/10.1007/s40268-020-00302-7
dc.identifier.uri	http://hdl.handle.net/10566/5516
dc.description.abstract	The pharmacokinetics of vancomycin, a drug used for the treatment of methicillin-resistant Staphylococcus aureus (MRSA), varies between paediatric and adult patients. The objective of this study was to assess the pharmacokinetics of vancomycin in preterm neonates and determine the optimum dose regimen.	en_US
dc.language.iso	en	en_US
dc.publisher	Springer Nature	en_US
dc.subject	Vancomycin pharmacokinetics	en_US
dc.subject	Dose regimen	en_US
dc.subject	Preterm Neonates	en_US
dc.subject	Adult patients	en_US
dc.subject	Paediatric	en_US
dc.title	Assessment of Vancomycin Pharmacokinetics and Dose Regimen Optimisation in Preterm Neonates	en_US
dc.type	Article	en_US